Wednesday, December 17, 2008 10:01:54 PM
Repros Therapeutics Inc. $ 10.82
RPRX 0.28
Short Interest (Shares Short) 933,200
Days To Cover (Short Interest Ratio) 11.3
Short Percent of Float 7.41 %
Short Interest - Prior 1,039,100
Short % Increase / Decrease -10.19 %
Short Squeeze Ranking™ 10
% From 52-Wk High ($ 11.09 ) -2.50 %
% From 52-Wk Low ($ 5.31 ) 50.92 %
% From 200-Day MA ($ 8.49 ) 21.53 %
% From 50-Day MA ($ 8.74 ) 19.22 %
Price % Change (52-Week) 11.80 %
Shares Float 12,600,000
Total Shares Outstanding 15,174,904
% Owned by Insiders 44.47 %
% Owned by Institutions 24.10 %
Market Cap. $ 164,192,461
Trading Volume - Today 79,200
Trading Volume - Average 82,300
Trading Volume - Today vs. Average 96.23 %
Earnings Per Share -1.76
PE Ratio
Record Date 2008-DecA
RPRX 0.28
Short Interest (Shares Short) 933,200
Days To Cover (Short Interest Ratio) 11.3
Short Percent of Float 7.41 %
Short Interest - Prior 1,039,100
Short % Increase / Decrease -10.19 %
Short Squeeze Ranking™ 10
% From 52-Wk High ($ 11.09 ) -2.50 %
% From 52-Wk Low ($ 5.31 ) 50.92 %
% From 200-Day MA ($ 8.49 ) 21.53 %
% From 50-Day MA ($ 8.74 ) 19.22 %
Price % Change (52-Week) 11.80 %
Shares Float 12,600,000
Total Shares Outstanding 15,174,904
% Owned by Insiders 44.47 %
% Owned by Institutions 24.10 %
Market Cap. $ 164,192,461
Trading Volume - Today 79,200
Trading Volume - Average 82,300
Trading Volume - Today vs. Average 96.23 %
Earnings Per Share -1.76
PE Ratio
Record Date 2008-DecA
Recent RPRX News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 08:11:40 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:55:58 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases • GlobeNewswire Inc. • 03/30/2026 11:15:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/23/2026 08:43:18 PM
- Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence • GlobeNewswire Inc. • 03/23/2026 11:15:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 09:12:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2026 10:02:29 PM
- Royalty Pharma Announces Expansion of Leadership Team • GlobeNewswire Inc. • 03/17/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:11:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:52:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:26:17 PM
- Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:10:00 AM
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:01:00 AM
- Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:08:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 10:06:45 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/20/2026 09:27:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:03:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:51 PM
